About Us
Services
News & events
- Blog
Contact
- Contact Us
- Email Alerts

IR Department Newsletter - March 2022

News & events >

Blog

Recent Posts

Watch, Look, Listen
And That's a Wrap: HealthInvest 2024
Equity Insights: September 2024
HealthInvest 2024
Meet our newest team member

Archives

October 2024
September 2024
August 2024
May 2024
December 2023
October 2023
July 2023
March 2023
February 2023
November 2022
October 2022
September 2022
August 2022
July 2022
March 2022
February 2022
January 2022
December 2021
October 2021
September 2021

Categories

AGMs
Crisis communications
Equity Insights
ESG
Investor relations
Newsletter March 2022
Newsletter Sept 2022
Uncategorized

A groundbreaking approach to cancer treatment

A number of breakthrough discoveries for Race Oncology's (ASX:RAC) drug Zantrene® over the past 18 months has seen the company evolve its strategy and clinical programs in order to maximise these opportunities. What does the future for Race look like?

Posted on March 16th, 2022 . Updated on March 23rd, 2022 by Paul Langley

Posted in Uncategorized

IR Department acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Subscribe

ASX Announcements

Media Releases & News

Which of the following group do you best fit?

Yes No

By subscribing you agree to with our Privacy Policy

Site Map Privacy Search

IR Department . All rights reserved. - Site by